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Abstract
Background: A study was undertaken to resolve preliminary conflicting results on the
proliferation of leukemia cells observed with different c-myc antisense oligonucleotides.
Results: RNase H-active, chimeric methylphosphonodiester / phosphodiester antisense
oligodeoxynucleotides targeting bases 1147–1166 of c-myc mRNA downregulated c-Myc protein
and induced apoptosis and cell cycle arrest respectively in cultures of MOLT-4 and KYO1 human
leukemia cells. In contrast, an RNase H-inactive, morpholino antisense oligonucleotide analogue
28-mer, simultaneously targeting the exon 2 splice acceptor site and initiation codon, reduced c-
Myc protein to barely detectable levels but did not affect cell proliferation in these or other
leukemia lines. The RNase H-active oligodeoxynucleotide 20-mers contained the phosphodiester
linked motif CGTTG, which as an apoptosis inducing CpG oligodeoxynucleotide 5-mer of sequence
type CGNNN (N = A, G, C, or T) had potent activity against MOLT-4 cells. The 5-mer mimicked
the antiproliferative effects of the 20-mer in the absence of any antisense activity against c-myc
mRNA, while the latter still reduced expression of c-myc in a subline of MOLT-4 cells that had been
selected for resistance to CGTTA, but in this case the oligodeoxynucleotide failed to induce
apoptosis or cell cycle arrest.
Conclusions: We conclude that the biological activity of the chimeric c-myc antisense 20-mers
resulted from a non-antisense mechanism related to the CGTTG motif contained within the
sequence, and not through downregulation of c-myc. Although the oncogene may have been
implicated in the etiology of the original leukemias, expression of c-myc is apparently no longer
required to sustain continuous cell proliferation in these culture lines.
Background
The v-myc gene was originally discovered as being the
cell transforming oncogene of the avian myelocytomato-
sis virus MC29, and was subsequently shown to be a vi-
rally sequestered copy of a member of a normal cellular
gene family [1]. The c-myc gene was subsequently found
to be overexpressed in a variety of human malignancies,
most notably in Burkitt lymphoma, through chromo-
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munoglobulin loci [2,3], and in other cancers through
gene amplification [2,4,5]. The gene product has been
shown to act as a transcription factor and has been impli-
cated in cell cycle control, while overexpression can con-
tribute to malignant transformation or result in
induction of programmed cell death [for detailed reviews
see [6–9]]. Results of experiments with an antisense oli-
godeoxynucleotide sequence targeting the initiation co-
don region of c-myc mRNA (bases 559–573 HSMYC1,
GenBank Accession Number V00568) [8,10,11] have
been taken as providing strong support for the generally
accepted view that expression of the gene is required for
passage of cells from G1 into S phase of the cell cycle [7].
In consideration of the foregoing, it was somewhat of a
surprise to us to find that we could reduce expression of
c-myc to low levels for several hours, following intracyto-
plasmic delivery of the same antisense sequence through
reversible plasma membrane permeabilization with
streptolysin O, but that such treatment had no effect on
the proliferation of cells of the human T lymphocytic
leukemia line, MOLT-4 [12]. The oligodeoxynucleotide
15-mer used in these experiments had a chimeric struc-
ture composed of 3 nuclease-resistant methylphospho-
nate internucleoside linkages at each end of the molecule
to protect against exonucleolytic degradation, and a cen-
tral section with 8 normal phosphodiester groups to elic-
it cleavage of c-myc mRNA by endogenous cellular
RNase H. In view of the transient nature of the suppres-
sion of c-myc gene expression, due to the intracellular
decay of intact antisense effector [12], attempts were
made to enhance the biological stability of the antisense
oligodeoxynucleotide, by reducing endonuclease suscep-
tibility through further methylphosphonate substitution.
However, these experiments served to demonstrate that
the initiation codon region of c-myc mRNA, which we re-
fer to as the A site, is involved in secondary structure and
is not a good target for antisense attack [13]. The methyl-
phosphonate modification is helix destabilising [14,15]
and just one further substitution abolished RNase H-me-
diated antisense activity at the initiation codon site [13],
while reduced phosphodiester structures targeting ap-
parently accessible regions in other mRNAs were still
highly active [16]. On the other hand, the downstream
region bounded by positions 1150–1159 of c-myc mRNA
was obviously readily accessible since it was efficiently
cleaved by RNase H in the presence of the initiation co-
don antisense oligodeoxynucleotide [17], through only
partial complementarity to the latter over the sequence
CGTTGAGG*GG within the oligomer (G* ignifies a GU
base pair in the hybrid between the A site antisense oli-
godeoxynucleotide and positions 1150–1159 of c-myc
mRNA). Chimeric methylphosphonate / phosphodiester
oligodeoxynucleotides fully complementary to positions
1147–1166 of c-myc mRNA, which we refer to as the D
site, and incorporating the sequence CGTTG within the
central phosphodiester section were shown to be highly
effective at ablating the message by an RNase H depend-
ent mechanism, as evidenced by the appearance of c-myc
mRNA fragments on Northern blots, and at reducing c-
Myc protein to low levels over 24 h in living leukaemia
cells [18]. These effects were accompanied by marked in-
hibition of cell proliferation that was initially ascribed to
the sustained downregulation of c-myc achieved through
targeting the new D site. However, this interpretation
was put in doubt when prolonged suppression of c-myc
gene expression, achieved with a morpholino antisense
oligonucleotide analogue 28-mer, simultaneously tar-
geting the exon 2 splice acceptor site and initiation codon
[19], failed to affect cell proliferation.
During the course of the above work we had also under-
taken an investigation into the observation that a ran-
dom sequence, control 15-mer oligodeoxynucleotide
rapidly induced apoptosis following intracytoplasmic de-
livery into MOLT-4 and Jurkat E6 human T lymphocytic
leukemia cells. The results of this study demonstrated
that the activity was due to the phosphodiester linked 5-
mer motif CGGTA present within the oligodeoxynucle-
otide, and that isolated, end-protected CpG 5-mers of se-
quence type CGNNN (N = A,G,C or T) induced apoptosis
with varying degrees of potency depending upon the na-
ture of the 3' terminal sequence [20]. The more active 5-
mers were also found to induce cell cycle arrest without
triggering apoptosis in a number of other leukemia cell
lines. The 5-mer sequence CGTTG, present within both
the A site, initiation codon c-myc antisense oligodeoxy-
nucleotide and the D site antisense effector, was one of
the most potent inducers of apoptosis / cell cycle arrest.
Why the A site antisense oligodeoxynucleotide failed to
induce apoptosis in MOLT-4 cells is readily explained by
the fact that the internucleoside methylphosphonate
substitution of the chimeric structure extended into the
CpG 5-mer motif [12], which was shown to abolish apop-
tosis inducing activity of CpG oligodeoxynucleotides
[20]. On the other hand the D site antisense oligodeoxy-
nucleotides contained CGTTG in fully phosphodiester
linked form [18] raising the possibility that the observed
antiproliferative effects were related to the non-anti-
sense biological activity of this motif rather than to the
antisense-induced downregulation of c-myc expression.
The situation is further complicated by the observation
that the sequences CGGTA and CGTTA, present within
15-mer oligodeoxynucleotides and as an isolated 5-mer
respectively, induced quite substantial reductions in the
levels of c-Myc protein expression in MOLT-4 and mye-
loid leukemia KYO1 cells by a non-antisense mechanism,
with lesser effects on the corresponding intracellular
concentrations of c-myc mRNA [20]. The present work
was undertaken to establish the relevance of c-myc ex-
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lines as opposed to CpG 5-mer effects. Our results dem-
onstrate that c-Myc protein may be severely reduced in
cells without affecting proliferation, suggesting that if
dysregulation of c-myc was involved in the etiology of the
source leukemias, its function has since been superseded
by other factors which maintain the cells in a permanent-
ly proliferative state.
Results
A range of chimeric methylphosphonodiester / phos-
phodiester antisense oligodeoxynucleotides (Table 1)
targeting bases 1147–1166 of human c-myc mRNA
(HSMYC1, GenBank Accession Number V00568), de-
rived from exon 2 and corresponding to codons 197–203
(part) of c-Myc protein, were evaluated for their effects
on c-myc gene expression following intracytoplasmic de-
livery into cells of the human chronic myeloid leukemia
line, KYO1. Molecules with stepwise reductions in the
number of central phosphodiester linkages from 9 to 4
exhibited high activity in inducing the ablation of c-myc
mRNA. Since c-Myc protein has a very short half-life
[13], its intracellular concentration reflected the reduc-
tions in the level of the mRNA (Figure 1A). Control oligo-
deoxynucleotides with an inverted antisense or sense
sequence had no significant effect on c-myc gene expres-
sion. Ablation of c-myc mRNA by the antisense oligode-
oxynucleotides resulted from an RNase H-mediated
mechanism directed by the central phosphodiester sec-
tion of the molecules. RNase H-generated fragments of
c-myc mRNA were visible on Northern blots of total
RNA isolated from treated KYO1 cells at 4 h, and essen-
tially the same results were observed whether intracyto-
plasmic delivery was achieved by reversible plasma
membrane permeabilization with streptolysin O or by
electroporation (Figure 1B). Figure 2A presents the dose
response for ablation of c-myc mRNA in cells loaded by
streptolysin O permeabilization from the indicated ex-
ternal concentrations of a chimeric antisense oligodeox-
ynucleotide 20-mer containing just 5 central
phosphodiester linkages. GAPDH mRNA was included
as a control for specificity in this experiment since it had
previously been shown to be susceptible to RNase H-me-
diated cleavage at high concentrations of c-myc D site
antisense oligodeoxynucleotides [18], through partial
complementarity over 9 consecutive bases from 967–975
(HSGAPDR, GenBank Accession Number X01677) and
11 overall between 961–980. It can be seen that cells be-
came arrested in the cell cycle (Figure 2B) at concentra-
tions of oligodeoxynucleotide which had significant
effects on c-myc mRNA and negligible effects on GAPDH
mRNA (Figure 2A).
In contrast to the foregoing, an RNase H-inactive mor-
pholino c-myc antisense oligonucleotide 28-mer, simul-
taneously targeting both the initiation codon and exon 2
splice acceptor sites of c-myc (Table 1), inhibited both
splicing and normal translation initiation, induced miss-
plicing to a cryptic site 44 nucleotides downstream of the
normal splice acceptor site thereby cutting out the AUG
initiation codon, and after around 4 h of inhibition, be-
gan to induce translation initiation from a downstream,
in frame AUG [19]. However, despite the almost com-
plete ablation of full length c-Myc protein over 24 h and
Figure 1
The effects of an RNase H-active, chimeric methylphosphon-
odiester / phosphodiester antisense oligodeoxynucleotide on
c-myc mRNA and c-Myc protein in KYO1 cells. (A) Relative
levels of mRNA and protein at 4 h post intracytoplasmic
delivery by streptolysin O permeabilization were determined
by densitometry of Northern and Western blots. Data rep-
resent the mean and standard deviation of 3 replicates. The
structures of the antisense oligodeoxynucleotide, and
inverted antisense and sense controls are given in Table 1.
(B) Northern blots of c-myc mRNA at 4 h following oligode-
oxynucleotide delivery by streptolysin O permeabilization
and by electroporation of KYO1 cells. Grey arrow; full
length mRNA. Black arrows; RNase H-generated 5' frag-
ments of mRNA.
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KYO1 cells continued to proliferate at the same rate as
cells permeabilized in the absence of oligonucleotide or
in the presence of sense and nonsense controls (Figure
3B). Similar results were observed with HL60 human
acute promyelocytic leukemia, U937 human histiocytic
leukemia and MOLT-4 human T lymphocytic leukemia
cells (data not shown).
The CpG motif, CGTTG, present within the central phos-
phodiester section of the chimeric methylphosphonodi-
ester / phosphodiester, c-myc antisense 20-mer, 5'F-
MD757AS (Table 1), also inhibited the proliferation of
Figure 2
Dose-response for ablation of c-myc mRNA and inhibition of
proliferation of KYO1 cells by a chimeric methylphosphono-
diester / phosphodiester antisense oligodeoxynucleotide.
Cells were loaded by streptolysin permeabilization from the
indicated external concentrations of oligodeoxynucleotide
5'F-MD757AS (Table 1). (A) Relative levels of c-myc and
GAPDH mRNA at 4 h. Mean and standard deviation of 3 rep-
licates. (B) Increase in cell number / ml over 20 h from an ini-
tial cell density of 5 × 105 / ml. Mean and standard deviation
of 3 replicates.
Figure 3
Effects of an RNase H-inactive morpholino antisense oligonu-
cleotide on c-myc mRNA, c-Myc protein, and proliferation of
KYO1 cells. The antisense, and control sense and nonsense
oligonucleotides (Table 1) were delivered into cells by strep-
tolysin O permeabilization from an external concentration of
20 µM. (A) Upper panels; Northern blots of mRNA at 4 and
24 h. Lower panels; Western blots of c-Myc protein at 4 and
24 h. The 47 kDa truncated protein containing the c-Myc
epitope recognised by the antibody mix resulted from initia-
tion of translation at an in-frame AUG 300 bases down-
stream of the c-Myc 2 AUG initiation codon [22]. (B) Cell
number relative to that at 2 h after loading cells with oligonu-
cleotide. Values are the mean and standard deviation of 3
replicates.
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was end-protected against exonuclease degradation by
fluorescein at the 5' end and 3-hydroxypropyl phosphate
at the 3' end (Figure 4A). In contrast to the large reduc-
tion in c-myc mRNA and appearance of RNase H-gener-
ated fragments at 30 min in cells treated with the full
length antisense 20-mer, CGTTG induced only a modest
drop in mRNA and no fragments were detectable on
Northern blots (Figure 4B). However, CGTTG treatment
did downregulate c-Myc protein, although this occurred
more slowly and to a somewhat lesser extent than in cells
loaded with the full length antisense 20-mer (Figure 4C).
Modest reductions in c-myc mRNA and more profound
decreases in c-Myc protein were previously observed in
KYO1 and MOLT-4 cells treated with other CpG oligode-
oxynucleotides [20]. Therefore, it was unlikely that
downregulation of c-Myc protein by CGTTG occurred
through an antisense mechanism. Indeed, unlike the c-
myc antisense 20-mer, CGTTG did not promote cleavage
of c-myc mRNA by E. coli RNase H, as determined by in-
cubation in vitro with total RNA isolated from KYO1
cells, followed by RT-PCR using c-myc specific primers
across the antisense target site (Figure 5). Both the c-
myc antisense 20-mer, 5'F-MD757AS and CGTTG rapid-
ly induced apoptosis in MOLT-4 cells and downregula-
tion of c-Myc protein was maintained over 4 h by both
treatments (Figure 6A and 6B). However, a MOLT-4 cell
subline generated for resistance to CpG 5-mers by repet-
itive treatments of surviving cells with CGTTA was also
resistant to the apoptogenic action of CGTTG and the c-
myc antisense 20-mer (Figure 6D). CGTTG also failed to
induce a significant effect on c-Myc protein expression in
this MOLT-4 subline (Figure 6C). Nevertheless, the true
RNase H-mediated antisense activity of 5'F'MD757AS
against c-myc mRNA was maintained and c-Myc protein
levels were severely reduced in CpG oligodeoxynucle-
otide-resistant cells loaded with the 20-mer (Figure 6C),
but the cells did not apoptose (Figure 6D). Consequently,
it is clear that once the propensity for CpG oligodeoxynu-
cleotide-induced apoptosis is removed, the previously
observed correlation between downregulation of c-Myc
protein and cell death no longer holds.
Discussion
In applying antisense oligonucleotides to dissect gene
function it is desirable to use two types of molecule em-
bodying different mechanisms of action against the tar-
get mRNA. It is unlikely that non-specific or
unanticipated sequence-specific biological activity will
be the same when the chemical structure of the oligonu-
cleotides and the strategy for blocking translation of the
message are widely different. Therefore, the assignment
of gene function can be made with greater confidence
when phenotypic effects of different types of antisense
oligonucleotide concur. We have targeted expression of
the c-myc gene in human leukemia cell lines using two
different antisense strategies. On the one hand, cleavage
of c-myc mRNA within the translated region by endog-
enous RNase H was induced through application of chi-
meric methylphosphonodiester / phosphodiester
Table 1: Structure and sequences of c-myc antisense and control oligonucleotides
Methylphosphonodiester / phosphodiester chimeric oligodeoxynucleotides
5'F-MD685AS 5'–Fluos-C/T/G/C/T/G/T-C-G-T-T-G-A-G-A/G/G/G/T/A–3'
AS targeting 1147–1166
5'F-MD586iAS 5'–Fluos-A/T/G/G/G/A-G-A-G-T-T-G-C-T/G/T/C/G/T/C–3'
Inverted AS control
5'F-MD586S 5'–Fluos-T/A/C/C/C/T-C-T-C-A-A-C-G-A/C/A/G/C/A/G–3'
Sense 1147–1166 control
5'F-MD757AS 5'–Fluos-C/T/G/C/T/G/T/C-G-T-T-G-A/G/A/G/G/G/T/A–3'
AS targeting 1147–1166
CpG oligodeoxynucleotide 5-mer
CGTTG 5 '–Fluos-C-G-T-T-G-ProOH–3'
CpG motif present in 1147–1166 AS and 559–573 AS
Morpholino oligonucleotide analogues
M28AS 5'–Fluos-GGC AUC GUC GCG GGA GGC UGC UGG AGC G–3'
AS targeting from within Intron 1 to 563
M28NS 5'–Fluos-CAG GCC UUG UGG ACG GCG GUU CGC GAG G–3'
Nonsense control
M28S 5'–Fluos-CGC UCC AGC AGC CUC CCG CGA CGA UGC C–3'
Sense from within Intron 1 to 563 control
/ = Methylphosphonodiester link; - = phosphodiester link; Fluos = fluorescein label; -ProOH = 3-hydroxypropyl phosphate group Numbering refers 
to base positions in c-myc mRNA (HSMYC1, GenBank Accession Number V00568)
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downregulated through steric blockade of both pre-
mRNA splicing and translation initiation using a mor-
pholino oligonucleotide analogue. In both cases the data
presented and reported previously [19,21] support the
conclusion that the anticipated mechanisms were en-
trained within the cells and that true antisense effects on
c-myc gene expression were achieved. However, in our
case the phenotypic effects in terms of cell proliferation
were contradictory.
The induction of apoptosis in MOLT-4 cells and cell cycle
arrest in KYO1 cultures by RNase H-active chimeric oli-
godeoxynucleotides targeting bases 1147–1166 of c-myc
mRNA were seemingly predictable results. The lack of ef-
fect of the morpholino antisense oligonucleotide on
leukemia cell proliferation was somewhat surprising, es-
pecially considering that ablation of c-Myc protein at 4h
was almost total (Figure 3). The accumulation of a pro-
tein of approximately 47 kDa carrying the c-Myc epitope
recognised by the antibody mix, clearly visible at 24 h,
was the result of initiation of translation at an in-frame
AUG exactly 300 bases downstream of the position of the
normal AUG initiation codon in c-myc mRNA. Such c-
Myc short proteins which lack most of the N-terminal
transactivation domain but retain the C-terminal protein
dimerization and DNA binding domains have been ob-
served in certain cells under normal growth conditions
[22]. They are unable to activate transcription and inhib-
it transactivation by full-length c-Myc protein. However,
in the present experiments both the full-length protein
and the truncated product were barely detectable at 4 h
after the initiation of antisense treatment (Figure 3), but
despite their absence the cells continued to proliferate at
the same rate as untreated controls. In view of the fore-
going it seemed likely that the biological activity of the
RNase H-active antisense oligodeoxynucleotides was
due to the action of the CGTTG motif present within the
phosphodiester section of the chimeric molecules, rather
than to downregulation of c-Myc protein. Apoptosis in-
duced by CpG oligodeoxynucleotide 5-mers in MOLT-4
cells was of rapid onset and was characterised by marked
redistribution of phosphatidylserine to the outer surface
of the plasma membrane and DNA laddering within 160
min, while the mitochondrial transmembrane potential
collapsed over roughly the same timescale [20]. The
process was associated with proteolytic processing of
pro-caspase 8 and Bid, followed by processing of pro-
caspase 3. It is noteworthy that the oligodeoxynucleotide
CGTTG was a potent inducer of apoptosis in MOLT-4
cells and that the relative activity of different 5-mers cor-
related with their ability to arrest KYO1 cells in the cell
cycle [20]. In the present work we have shown that
CGTTG mimicked the antiproliferative effects of the
RNase H-active 20-mers in the absence of any antisense
activity against c-myc mRNA (Figures 4 and 6). We have
also demonstrated that once MOLT-4 cells are rendered
resistant to CpG oligodeoxynucleotide-induced apopto-
sis they no longer undergo programmed cell death or
even cell cycle arrest in response to downregulation of c-
Myc by a chimeric antisense 20-mer (Figure 6C and 6D).
Figure 4
Comparison of the chimeric c-myc antisense 20-mer, 5’F-
MD757AS (Table 1) with the CpG 5-mer motif CGTTG con-
tained within its phosphodiester section for effects on c-myc
mRNA, c-Myc protein and proliferation of KYO1 cells. Cells
were loaded with oligodeoxynucleotide by streptolysin O
permeabilization from an external concentration of 20 µM.
(A) Cell proliferation over 24 h. (B) Levels of full length c-myc
mRNA 30 min after oligodeoxynucleotide delivery. RNase
H-generated mRNA fragments were visible on the Northern
blot for cells treated with the 20-mer but not the 5-mer. (C)
Relative levels of c-Myc protein. Values in all panels are the
mean and standard deviation of 3 replicates.
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sion to cell cycle control [6,7,9], it would appear that its
functions have been superseded by other dominant path-
ways in the established leukemia cell lines. This raises
the question as to whether independence from c-myc
was selected for during establishment of immortal cell
cultures, or occurred prior to this during malignant pro-
gression in vivo. It has generally been assumed that ex-
pression of the oncogene would be critical for
maintaining the malignant phenotype of leukemic leuko-
cytes since it was shown to be upregulated in these cells
[3,4]. This relies on the logic that if a protein is there and
expressed in abundance, then it must be doing some-
thing, which is not necessarily true. It may well be that
overexpression of c-myc serves to select for cells that are
insensitive to its activities, such as induction of apopto-
sis, and that the accompanying genetic changes contrib-
ute to malignant progression without the further
requirement for elevated c-Myc protein [8,9,25–27]. Our
future work will address this question using primary
leukemia cells derived from patients before and during
therapy.
Conclusions
We have shown that use of antisense oligonucleotides in
assessing gene function may lead to spurious assign-
ments, if not properly controlled by confirmation
through independent strategies. Conflicting results of
such an approach prompted this investigation, which has
led to the conclusion that expression of c-myc is not crit-
ical for cell proliferation in the established leukemia lines
studied. Rather the CpG 5-mer motif present in the anti-
sense oligodeoxynucleotide sequence, and not downreg-
ulation of c-myc, was responsible for the observed
biological activity, leading to apoptosis and cell cycle ar-
rest by a non-antisense mechanism. This is an important
finding which needs to be taken into account in defining
the true functions of c-myc in dividing cells. It raises the
question as to whether expression of the oncogene is re-
quired to sustain uncontrolled proliferation in primary
malignant cells, and if not, then why is the gene ampli-
fied / overexpressed in leukemia and lymphoma. Finally,
apart from the importance of avoiding CpG 5-mer motifs
in antisense oligodeoxynucleotides, the unusual biologi-
cal activity of these small oligodeoxynucleotides presents
the opportunity to define novel targets for antileukemic
drug development.
Materials and Methods
Cell lines
The human T cell leukemia line MOLT-4, the human
acute promyelocytic leukemia HL60 and the histiocytic
lymphoma line U937 were supplied by the European Col-
lection of Animal Cell Cultures (PHLS Centre for Applied
Microbiology and Research, Porton Down, Wiltshire,
UK). The chronic myeloid leukemia line KYO1 was do-
nated by the LRF Leukaemia Unit, Hammersmith Hos-
pital (London, UK). Cells were maintained in
exponential growth in RPMI 1640 medium supplement-
ed with L-glutamine (GibcoBRL, Paisley, Renfrewshire,
UK) and 10% heat-inactivated fetal bovine serum (Har-
lan Sera-Lab Ltd, Crawley Down, West Sussex, UK). Cell
number per ml was determined on a Coulter Counter ZM
(Coulter Electronics Ltd, Luton, Bedfordshire, UK). Via-
ble cell number per ml was measured by flow cytometry
of cells excluding propidium iodide on an Ortho Cytoron
Absolute (Ortho Diagnostic Systems Ltd, High Wy-
combe, Buckinghamshire, UK).
Oligodeoxynucleotide synthesis and cell treatment
Chimeric methylphosphonodiester / phosphodiester oli-
godeoxynucleotides were synthesized as described previ-
Figure 5
Assay in vitro for oligodeoxynucleotide activity with E. coli
RNase H against c-myc mRNA in total RNA isolated from
KYO1 cells. Reaction mixtures containing 1 µg RNA and 0.5
U RNase H in 18 µl were incubated at 37°C for 30 min in the
presence, where indicated, of 22 µM oligodeoxynucleotide.
Following RT-PCR with c-myc-specific primers straddling the
antisense target site, products were separated by 1.5% agar-
ose / ethidium bromide gel electrophoresis and viewed
under UV light. M, markers. The expected product size from
uncleaved mRNA is 899 bp. Lane 11 was loaded with a no
oligodeoxynucleotide, no reverse transcriptase control. Only
lanes 3 and 4 loaded with 20-mer antisense replicates
showed reductions in signal intensity consistent with signifi-
cant RNase H-mediated cleavage of c-myc mRNA.
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phosphoramidite synthons (Glen Research, Sterling, VA;
UK supplier Cambio Ltd, Cambridge). 5'-Amino-Modifi-
er C6-TFA (Glen Research) was incorporated in the final
cycle of the synthesis and the oligodeoxynucleotides
were labelled with fluorescein, postsynthesis, using Flu-
os reagent (Roche Diagnostics Ltd, Lewes, East Sussex,
UK). Oligodeoxynucleotides terminating at their 3' ends
with phosphodiester internucleoside linkages were syn-
thesized on DMT-C3-Succinyl-CPG support (Peninsula
Laboratories Europe Ltd, St Helens, Merseyside, UK) to
provide protection against 3'-exonuclease by a 3-hydrox-
ypropyl phosphate group on the 3'-OH. Fluorescein
tagged morpholino oligonucleotide analogues were gen-
erously donated by AntiVirals, Inc. (Corvallis, OR). Oli-
gonucleotides were introduced into the cytoplasm of
cells by 10 min reversible permeabilization of the plasma
membrane with streptolysin O (Sigma-Aldrich Company
Ltd, Poole, Dorset, UK) in the presence of external con-
centrations of 0.002–20 µM oligonucleotide in serum-
free RPMI 1640, as previously described [12]. A full ex-
perimental protocol for this technique is available at the
web site of The Antisense Research Group at The Univer-
sity of Liverpool  [http://www.liv.ac.uk/~giles] . Alter-
natively, cells were electroporated in the presence of
oligonucleotide under the reported conditions [24]. Re-
sults presented represent cultures in which >85% of the
cells had taken up the oligodeoxynucleotide and subse-
quently resealed to exclude propidium iodide as deter-
mined by dual parameter flow cytometry.
Northern and Western blotting
Effects on cellular content of mRNAs and protein were
determined by densitometry of Northern and Western
blots as previously described [13,18].
In vitro RNase H assays
Total RNA isolated from KYO1 cells was diluted to a con-
centration of 1 µg/18 µl reaction volume in complete
First Strand Buffer mix (GibcoBRL) containing 0.4 nmol
oligodeoxynucleotide and 0.5 U E. coli RNase H (Boe-
hringer Mannheim UK Ltd, Lewes, East Sussex, UK). Re-
action mixtures were incubated at 37°C for 30 min. The
reaction was terminated by heating at 70°C for 10 min,
and first strand cDNA synthesis was carried out using
200 U Superscript II (GibcoBRL) and 60 pmol random
9-mer oligodeoxynucleotide primers according to the
manufacturer's instructions. Samples (1 µl) of the re-
verse transcription reactions were subjected to PCR am-
plification using an oligodeoxynucleotide corresponding
to bases 368–397 of c-myc mRNA (GenBank Accession
Number V00568) as the upstream primer (CG-
GGCACTTTGCACTGGAACTTACAACACC), and the
complement of bases 1221–1243 plus a 5' 23 base T7 pro-
moter sequence as the downstream primer
(GCGTAATACGACTCACTATAGGGACTCCGTCGAGG
AGAGCAGAGAA), to yield a 899 bp product from uncut
message. Products were separated by 1.5 % agarose /
ethidium bromide (1 µg/ml) gel electrophoresis.
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